Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    1.2500
  • TODAY'S CHANGE (%)
    0.0100 (0.8065%)
  • Bid / Lots
    1.2200/ 8
  • Ask / Lots
    1.2700/ 3
  • Open / Previous Close
    1.2200 / 1.2400
  • Day Range
    1.2100
    1.2600
  • 52 Week Range
    1.0500
    11.8904
  • Volume
    44,281

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

      Show headlines and story abstract

    • 4:30PM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: BCLI

      Conference call planned for later in Q4 2024 to provide updates on NurOwn(R) program

      BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.

    • 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: BCLI

      mwood@lifesciadvisors.com
      BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) -------------------- ------------------------ -------------- September 30, December 31, ------------------------ -------------- 2024 2023 ------------------------ -------------- Unaudited Audited ------------------------ -------------- U.S. $ in thousands ---------------------------------------- ASSETS -------------------- Current Assets: Cash and cash equivalents $ 168 $ 1,300 Other accounts receivable 40 51 Prepaid expenses and other current assets (Note 4) 156 548 ------------- --------- ---------- Total current assets $ 364 $ 1,899 ------------- --------- ---------- Long-Term Assets: Prepaid expenses and other long-term assets $ 22 $ 22 Restricted Cash 181 185 Operating lease right of use asset (Note 5) 959 1,416 Property and Equipment, Net 499 686 ------------- --------- ---------- Total Long-Term Assets $ 1,661 $ 2,309 ============= ========= ========== Total assets $ 2,025 $ 4,208 ============= ========= ========== LIABILITIES AND STOCKHOLDERS' DEFICIT -------------------- Current Liabilities: Accounts payables $ 4,603 $ 4,954 Accrued expenses 865 1,240 Operating lease liability (Note 5) 570 603 Employees related liability 1,044 1,003 ------------- --------- ---------- Total current liabilities $ 7,082 $ 7,800 ------------- --------- ---------- Long-Term Liabilities: Operating lease liability (Note 5) 271 672 Warrants liability (Note 6) 729 594 ------------- --------- ---------- Total long-term liabilities $ 1,000 $ 1,266 ------------- --------- ---------- Total liabilities $ 8,082 $ 9,066 Stockholders' Deficit: Stock capital: (Note 7) 14 13 Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at September 30, 2024 and 100,000,000 shares at December 31, 2023 respectively; Issued and outstanding: 5,309,796 and 4,032,614 shares at September 30, 2024 and December 31, 2023 respectively (*) Additional paid-in-capital 217,708 210,258 Treasury stocks (116) (116) Accumulated deficit (223,663) (215,013) ------------- --------- ---------- Total stockholders' deficit $ (6,057) $ (4,858) ============= ========= ========== Total liabilities and stockholders' deficit $ 2,025 $ 4,208 ============= ========= ========== * Retroactively adjusted (See Note 7).

    • 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: BCLI

  • Nov 11, 2024

Peers Headlines